Your browser doesn't support javascript.
loading
BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma.
Dutta, Debasmita; Liu, Jiye; Wen, Kenneth; Kurata, Keiji; Fulciniti, Mariateresa; Gulla, Annamaria; Hideshima, Teru; Anderson, Kenneth C.
Afiliação
  • Dutta D; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Liu J; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Wen K; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Kurata K; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Fulciniti M; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Gulla A; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Hideshima T; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. teru_hideshima@dfci.harvard.edu.
  • Anderson KC; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. kenneth_anderson@dfci.harvard.edu.
Blood Cancer J ; 13(1): 184, 2023 12 11.
Article em En | MEDLINE | ID: mdl-38072962
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo / Antineoplásicos Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo / Antineoplásicos Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article